In the United States, to opt for its COVID-19 vaccine, Pfizer calls on 12-15-year-olds.



The pharmaceutical company had announced days ago that the inoculant showed 100% effectiveness in this demographic group.

Pfizer requested this Friday that the United States health authorities authorize the application of its vaccine against COVID-19 in adolescents between 12 and 15 years old. The order comes nine days after the drugmaker announced that the inoculant had shown 100 percent efficacy in this demographic.

In a joint statement with the German BioNtech, with which it produces the immunizer, it also indicated that "they plan to make similar requests to other regulatory authorities around the world in the coming days ."

On March 31, the companies released data from their phase 3 clinical trials conducted on 2,260 adolescents in the United States. They " showed 100% efficacy and a robust antibody response, " prompting them to express their hope of being able to vaccinate as many adolescents as possible before the start of the next school year in the Northern Hemisphere.

Both the European Union and the United States have approved its use for people over the age of 16. Several states of the North American country have begun to apply it to these groups in recent days after the authorities enabled all authorized demographic groups' immunization.

President Joe Biden announced Tuesday that all people of these ages would be eligible to be inoculated by April 19, several days before the already ambitious previous goal of May 1.

Biotech, fearful of vaccinating the world, said on Tuesday that it was on track to produce 2.5 billion doses of its vaccine this year. 

Increased production has been affected by the recent launch of a new production site in Marburg's German city, now one of the largest mRNA vaccine manufacturing plants. The new technology used by both these pharmaceutical companies and Moderna - of the world.

The vaccine is being developed at a Pfizer plant in Belgium and three locations in the United States. BioNTech said improved efficiency and new cooperative agreements with external partners had also helped raise its vaccine target, as had regulatory go-ahead that allows vaccinators to draw six instead of just five doses from a single vial.

The companies also began studies of the injection in children in late March, with the first group of children aged five to 11 years already receiving the vaccine. Results are also expected for a younger group - ages two to five - to receive their first dose next week in the study, which will also cover children up to six months of age.

Modern pharmaceutical companies and Johnson & Johnson - whose inoculants have also received emergency authorization and the others are being applied in the United States - have also begun studies of the same nature.

In contrast, the University of Oxford indicated on Tuesday that it stopped the administration of doses of the vaccine against COVID-19 that it developed together with AstraZeneca to minors, pending more information on rare blood clotting problems (thrombosis) in adults who have received it.

An Oxford spokesman quoted by The Wall Street Journal said Tuesday that no safety issue has so far emerged in the trial itself, but there are general concerns about rare clotting problems in vaccinated adults. In fact, the issue prompted further regulatory reviews in the UK and Europe to investigate any potential links to the vaccine.